Abstract
We previously described the development of a predictive blood test for brain amyloid based on the combined use of eight aptamers (Aptamarkers) and the clinical variable, patient age with a sensitivity of 88%, specificity of 76% and an overall accuracy of 81%. This test results from an agnostic application of a defined library of 4.29 billion aptamer sequences to plasma samples derived from individuals with varying amounts of brain amyloid deposition. In this report, the same eight Aptamarkers and corresponding predictive algorithm were applied to plasma samples from 36 patients diagnosed with memory impairment in a memory clinic in Portugal. The patients were all subjected to cerebrospinal fluid (CSF) analysis with Aβ40, Aβ4 peptides, p181-tau and total tau characterization. The plasma analysis with the Aptamarkers resulted in a sensitivity of 73%, specificity of 71% and overall accuracy of 72% when considering brain amyloid alone. The predictive power when considering the diagnosis of Alzheimer’s disease based on a complete CSF analysis was a sensitivity of 68%, a specificity of 76% and an overall accuracy of 72%. These results in this diagnostic accuracy study are very similar to results obtained with model building on AIBL cohort. As such, this study demonstrates the potential efficacy of this simple qPCR assay as a basis for inclusion for subsequent CSF confirmation of brain amyloid deposition in a clinical setting.
Competing Interest Statement
The research was funded by NeoNeuro and Roche Diagnostica, Portugal. The authors, including Cathal Meehan, Soizic Lecocq, and Gregory Penner, are paid employees of NeoNeuro.
Funding Statement
This research was fully funded by NeoNeuro and Roche Diagnostica, Portugal through their participation in the Building Tomorrow Together Initiative, coordinated by Beta -I, Portugal. None of the authors received separate grant money for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research processes received ethical approval from the Ethics and Health Committee of Centro Hospitalar Entre o Douro e Vouga, Santa Maria da Feira, under the approval number n.53/2022. Informed consent was obtained from all participants or their legal representatives, who were informed about the study's objectives, procedures, and potential risks in accordance with the Declaration of Helsinki. Eligible patients who underwent CSF analysis in the second semester of 2023 and fulfilled the inclusion criteria were consecutively invited to participate in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
A different machine learning model was developed with different statistics
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- AD
- Alzheimer’s disease
- AIBL
- Australian imaging, biomarkers, and lifestyle
- CHEDV
- Centro Hospitalar de Entre Douro e Vouga
- CSF
- Cerebrospinal fluid
- CT
- Computed Axial Tomography
- GNPs
- Gold nanoparticles
- IDT
- Integrated DNA Technologies
- MCI
- Mild cognitive impairment
- MRI
- Magnetic resonance imagery
- NFL
- Neurofilament light chain
- PBS
- Phosphate buffer saline
- PCR
- Polymerase chain reaction
- qPCR
- Quantitative polymerase chain reaction
- RTp
- Relative template proportion
- TCEP
- Tris (2carboxyethyl) phosphine